<?xml version="1.0" encoding="UTF-8"?>
<p>Patients were eligible for this trial if they met the following criteria: age &gt;18 years; a diagnosis of acute leukemia, chronic myelogenous leukemia, myeloproliferative disease, myelodysplasia with less than 5% of blasts in the bone marrow, or a diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma or Hodgkin lymphoma with chemosensitive disease; availability of a 10/10 matched sibling or 8/8 matched unrelated donor; ejection fraction at rest &gt;45% for MA conditioning or &gt;40% for reduced intensity conditioning (RIC); estimated creatinine clearance greater than 50 mL/minute; adjusted diffusing capacity for carbon monoxide (DLCO) ≥40% and forced expiratory volume in 1 second (FEV1) ≥50%; and total bilirubin &lt; 1.5 × and alanine transaminase (ALT)/aspartate transaminase (AST) &lt; 2.5× the upper normal limit. Patients were excluded if they had had a prior allogeneic HSCT, Karnofsky Performance Score &lt;70%, uncontrolled bacterial, viral or fungal infections at time of enrollment, prior intolerance or allergy to Toc, use of rituximab, alemtuzumab, antithymocyte globulin (ATG) or other monoclonal antibody at time of conditioning regimen, or history of diverticulitis, Crohn's disease, ulcerative colitis or a demyelinating disorder.</p>
